Amgen Asks FDA to Expand Prolia’s Approval to Include an Additional Osteoporosis Condition

Amgen Asks FDA to Expand Prolia’s Approval to Include an Additional Osteoporosis Condition
Amgen has asked the U.S. Food and Drug Administration to expand its approval of the bone-building therapy Prolia (denosumab) to include an additional osteoporosis condition. The initial authorization covered men with metastatic prostate cancer who are at high risk of a fracture from the androgen deprivation therapy used to treat their disease. It also covered two osteoporosis conditions. Amgen has submitted

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *